source
- ProMis shares tumble after competitor's Alzheimer trial failure, CEO calls reaction overblownProMis Neurosciences, developer of an amyloid‑targeting Alzheimer’s therapy, saw its stock plunge sharply last week. The decline came after Acumen Pharmaceuticals announced that its own amyloid‑ta…
- Health systems grapple with AI chatbot use, some block tools while others consider in-house solutionsFree AI chatbots designed for clinicians, such as OpenEvidence, Doximity Ask and ChatGPT for Clinicians, have become popular, with hundreds of thousands of doctors turning to them for clinical guid…